Strengthening Health System and Community Mobilization for Sickle Cell Disease Screening and Management among Tribal Populations in India : An Interventional Study
Sickle cell disease (SCD) affects 5% of the global population, with over 300,000 infants born yearly. In India, 73% of those with the sickle hemoglobin gene belong to indigenous tribes in remote regions lacking proper healthcare. Despite the prevalence of SCD, India lacked state-led public health programs until recently, leaving a gap in screening and comprehensive care. Hence, the Indian Council of Medical Research conducted implementation research to address this gap. This paper discusses the development and impact of the program, including screening and treatment coverage for SCD in tribal areas. With a quasi-experimental design, this study was conducted in six tribal-dominated districts in three phases - formative, intervention, and evaluation. The intervention included advocacy, partnership building, building the health system's capacity and community mobilization, and enabling the health systems to screen and manage SCD patients. The capacity building included improving healthcare workers' skills through training and infrastructure development of primary healthcare (PHC) facilities. The impact of the intervention is visible in terms of people's participation (54%, 76% and 93% of the participants participated in some intervention activities, underwent symptomatic screening and demanded the continuity of the program, respectively), and improvement in SCD-related knowledge of the community and health workers (with more than 50% of net change in many of the knowledge-related outcomes). By developing screening and treatment models, this intervention model demonstrated the feasibility of SCD care at the PHC level in remote rural areas. This accessible approach allows the tribal population in India to routinely seek SCD care at their local PHCs, offering great convenience. Nevertheless, additional research employing rigorous methodology is required to fine-tune the model. National SCD program may adopt this model, specifically for community-level screening and management of SCD in remote and rural areas.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Hemoglobin - 47(2023), 6 vom: 23. Nov., Seite 227-236 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Babu, Bontha V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Comprehensive care |
|---|
| Anmerkungen: |
Date Completed 23.01.2024 Date Revised 23.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/03630269.2023.2300675 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366797735 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366797735 | ||
| 003 | DE-627 | ||
| 005 | 20240123232007.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03630269.2023.2300675 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1268.xml |
| 035 | |a (DE-627)NLM366797735 | ||
| 035 | |a (NLM)38189147 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Babu, Bontha V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Strengthening Health System and Community Mobilization for Sickle Cell Disease Screening and Management among Tribal Populations in India |b An Interventional Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.01.2024 | ||
| 500 | |a Date Revised 23.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Sickle cell disease (SCD) affects 5% of the global population, with over 300,000 infants born yearly. In India, 73% of those with the sickle hemoglobin gene belong to indigenous tribes in remote regions lacking proper healthcare. Despite the prevalence of SCD, India lacked state-led public health programs until recently, leaving a gap in screening and comprehensive care. Hence, the Indian Council of Medical Research conducted implementation research to address this gap. This paper discusses the development and impact of the program, including screening and treatment coverage for SCD in tribal areas. With a quasi-experimental design, this study was conducted in six tribal-dominated districts in three phases - formative, intervention, and evaluation. The intervention included advocacy, partnership building, building the health system's capacity and community mobilization, and enabling the health systems to screen and manage SCD patients. The capacity building included improving healthcare workers' skills through training and infrastructure development of primary healthcare (PHC) facilities. The impact of the intervention is visible in terms of people's participation (54%, 76% and 93% of the participants participated in some intervention activities, underwent symptomatic screening and demanded the continuity of the program, respectively), and improvement in SCD-related knowledge of the community and health workers (with more than 50% of net change in many of the knowledge-related outcomes). By developing screening and treatment models, this intervention model demonstrated the feasibility of SCD care at the PHC level in remote rural areas. This accessible approach allows the tribal population in India to routinely seek SCD care at their local PHCs, offering great convenience. Nevertheless, additional research employing rigorous methodology is required to fine-tune the model. National SCD program may adopt this model, specifically for community-level screening and management of SCD in remote and rural areas | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Sickle cell disease | |
| 650 | 4 | |a comprehensive care | |
| 650 | 4 | |a implementation research | |
| 650 | 4 | |a screening | |
| 650 | 4 | |a treatment | |
| 700 | 1 | |a Sharma, Yogita |e verfasserin |4 aut | |
| 700 | 1 | |a Sridevi, Parikipandla |e verfasserin |4 aut | |
| 700 | 1 | |a Surti, Shaily B |e verfasserin |4 aut | |
| 700 | 1 | |a Bhat, Deepa |e verfasserin |4 aut | |
| 700 | 1 | |a Ranjit, Manoranjan |e verfasserin |4 aut | |
| 700 | 1 | |a Sudhakar, Godi |e verfasserin |4 aut | |
| 700 | 1 | |a Sarmah, Jatin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hemoglobin |d 1993 |g 47(2023), 6 vom: 23. Nov., Seite 227-236 |w (DE-627)NLM000202541 |x 1532-432X |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2023 |g number:6 |g day:23 |g month:11 |g pages:227-236 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/03630269.2023.2300675 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2023 |e 6 |b 23 |c 11 |h 227-236 | ||